Bleeding as a predictor of mortality risk

Reviews in Cardiovascular Medicine

Volumn 7, Issue SUPPL. 3, 2006, Pages

  Rao, Sunil V ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Glycoprotein inhibitors; Myocardial infarction; Percutaneous coronary intervention; Thrombosis; Unfractionated heparin

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; NITRIC OXIDE; OXYGEN; THIENOPYRIDINE DERIVATIVE; THROMBIN; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION RISK; KIDNEY DISEASE; MONOTHERAPY; MORTALITY; OPTIMAL DRUG DOSE; OXYGEN SUPPLY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RECOMMENDED DRUG DOSE; RISK FACTOR; SEX DIFFERENCE; ST SEGMENT ELEVATION; THROMBOGENESIS; TISSUE OXYGENATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT CONTRAINDICATION; UNSTABLE ANGINA PECTORIS; VIRUS INFECTION;

ANTICOAGULANTS; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CORONARY DISEASE; HUMANS; MYOCARDIAL REVASCULARIZATION; POSTOPERATIVE HEMORRHAGE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 33846290732     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Smith SC, Jr, Feldman TE, Hirshfeld JW, Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47:e1-e121.
2. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
3. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
4. Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96:1200-1206.
5. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24: 1815-1823.
6. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92:930-935.
7. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555-1562.
8. Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N Engl J Med. 2000;342:101-114.
9. Ferguson JJ, Barasch E, Wilson JM, et al. The relation of clinical outcome to dissection and thrombus formation during coronary angioplasty. Heparin Registry Investigators. J Invas Cardiol. 1995;7:2-10.
10. Narins CR, Hillegass WB Jr, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation. 1996;93:667-671.
11. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994;23:1061-1065.
12. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037-2044.
13. Steinhubl SR, Berger PB, Mann JT, 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
14. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation. 1997;96:1445-1453.
15. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
16. Attubato MJ, Felt F, Bittl JA, et al. Major hemorrhage is an independent predictor of 1-year mortality following percutaneous coronary intervention: an analysis from REPLACE-2 (abstract). Am J Cardiol. 2004;94(suppl 1):39E.
17. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001;103:961-966.
18. Tolleson TR, O'Shea JC, Bittl JA, et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol. 2003;41;386-393.
19. Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):576S-599S.
20. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337:447-452.
21. Anand SS, Yusuf S, Pogue J, et al., for Organization to Assess Strategies for Ischemic Syndromes Investigators. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation. 2003;107:2884-2888.
22. Alexander KP, Chen AY, Roe MT, et al., for CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108-3116. Erratum in: JAMA. 2006;295:628.
23. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952-959.
24. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002; 143:847-853.
25. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol. 2004;93:1092-1096.
26. Lincoff AM, Bittl JA, Harrington PA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863.
27. Voeltz MD, Lincoff AM, Felt F, Manoukian SV. Bivalirudin significantly reduces bleeding while maintaining efficacy compared to either abciximab or eptifibatide in percutaneous coronary intervention: lessons from REPLACE-2. Abstract presented at: American Heart Association Scientific Sessions; November 13-16, 2005; Dallas, TX.
28. Goodnough LT, Soegiarso RW, Birkmeyer JD, Welch HG. Economic impact of inappropriate blood transfusions in coronary artery bypass graft surgery. Am J Med. 1993;94:509-514.
29. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts - blood conservation. N Engl J Med. 1999; 340:525-533.
30. Fortune JB, Feustel PJ, Saifi J, et al. Influence of hematocrit on cardiopulmonary function after acute hemorrhage. J Trauma. 1987;27: 243-249.
31. Casutt M, Seifert B, Pasch T, et al. Factors influencing the individual effects of blood transfusions on oxygen delivery and oxygen consumption. Crit Care Med. 1999;27:2194-2200.
32. Dietrich KA, Conrad SA, Hebert CA, et al. Cardiovascular and metabolic response to red blood cell transfusion in critically ill volume-resuscitated nonsurgical patients. Crit Care Med. 1990; 18:940-944.
33. McMahon TJ, Moon RE, Luschinger BP, et al. Nitric oxide in the human respiratory cycle. Nat Med. 2002;8:711-717.
34. Stamler JS, Jia L, Eu JP, et al. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science. 1997;276:2034-2037.
35. Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med. 1992;116:393-402.
36. Fransen E, Maessen J, Dentener M, et al. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest. 1999;116:1233-1239.
37. Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001;345:1230-1236.
38. Manoukian SV, Voeltz MD, Attubato MJ, et al. Bivalirudin reduces the risk of transfusion-associated mortality in patients undergoing percutaneous coronary intervention. Abstract presented at: Cardiovascular Revascularization Therapies; March 28-31, 2005; Washington, DC.
39. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340:409-417. Erratum in: N Engl J Med. 1999;340:1056.